Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1980 2
1981 2
1982 1
1983 1
1984 1
1989 3
1991 1
1997 1
1999 1
2000 1
2001 1
2002 1
2004 3
2005 1
2006 2
2007 2
2008 2
2009 4
2010 3
2011 3
2013 2
2014 5
2015 5
2016 9
2017 11
2018 7
2019 6
2020 8
2021 11
2022 5
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, de Bono JS. Antonarakis ES, et al. Among authors: fukasawa s. J Clin Oncol. 2020 Feb 10;38(5):395-405. doi: 10.1200/JCO.19.01638. Epub 2019 Nov 27. J Clin Oncol. 2020. PMID: 31774688 Free PMC article. Clinical Trial.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Procopio G, McDermott DF, Castellano D, Choueiri TK, Donskov F, Gurney H, Oudard S, Richardet M, Peltola K, Alva AS, Carducci M, Wagstaff J, Chevreau C, Fukasawa S, Tomita Y, Gauler TC, Kollmannsberger CK, Schutz FA, Larkin J, Cella D, McHenry MB, Saggi SS, Tannir NM. Motzer RJ, et al. Among authors: fukasawa s. Cancer. 2020 Sep 15;126(18):4156-4167. doi: 10.1002/cncr.33033. Epub 2020 Jul 16. Cancer. 2020. PMID: 32673417 Free PMC article. Clinical Trial.
Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review.
Yonese J, Hinata N, Masui S, Nakai Y, Shirotake S, Takeuchi A, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamana K, Miyake H, Fukasawa S, Morishima N, Ito H, Uemura H. Yonese J, et al. Among authors: fukasawa s. Int J Urol. 2023 Sep;30(9):762-771. doi: 10.1111/iju.15206. Epub 2023 May 29. Int J Urol. 2023. PMID: 37248753
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.
Eto M, Takagi T, Kimura G, Fukasawa S, Tamada S, Miura Y, Oya M, Sassa N, Anai S, Nozawa M, Sakai H, Perini R, Yusa W, Ikezawa H, Narita T, Tomita Y. Eto M, et al. Among authors: fukasawa s. Cancer Med. 2023 Mar;12(6):6902-6912. doi: 10.1002/cam4.5483. Epub 2022 Dec 1. Cancer Med. 2023. PMID: 36457273 Free PMC article. Clinical Trial.
Structure-Activity Relationship and In Silico Evaluation of cis- and trans-PCPA-Derived Inhibitors of LSD1 and LSD2.
Niwa H, Watanabe C, Sato S, Harada T, Watanabe H, Tabusa R, Fukasawa S, Shiobara A, Hashimoto T, Ohno O, Nakamura K, Tsuganezawa K, Tanaka A, Shirouzu M, Honma T, Matsuno K, Umehara T. Niwa H, et al. Among authors: fukasawa s. ACS Med Chem Lett. 2022 Aug 18;13(9):1485-1492. doi: 10.1021/acsmedchemlett.2c00294. eCollection 2022 Sep 8. ACS Med Chem Lett. 2022. PMID: 36105323 Free PMC article.
95 results